Cart
sales@molnova.com
GPAT-IN-1
CAS No. 1204347-51-2
GPAT-IN-1( —— )
Catalog No. M37313 CAS No. 1204347-51-2
GPAT-IN-1 is a glycerol 3-phosphate acyltransferase (GPAT) inhibitor, which can be used to study obesity and diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 52 | Get Quote |
|
| 5MG | 70 | Get Quote |
|
| 10MG | 101 | Get Quote |
|
| 25MG | 159 | Get Quote |
|
| 50MG | 236 | Get Quote |
|
| 100MG | 340 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGPAT-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionGPAT-IN-1 is a glycerol 3-phosphate acyltransferase (GPAT) inhibitor, which can be used to study obesity and diabetes.
-
DescriptionGPAT-IN-1 is a glycerol-3-phosphate acyltransferase (GPAT) inhibitor with an IC50 value of 8.9 μM. GPAT-IN-1 can be used for the research of obesity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetTransferase
-
RecptorTransferase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1204347-51-2
-
Formula Weight423.95
-
Molecular FormulaC21H26ClNO4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(O)C=1C=C(C=CC1NS(=O)(=O)CCCCCCCC)C2=CC=CC(Cl)=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Outlaw VK, et al. Design, Synthesis, and Evaluation of 4- and 5-Substituted o-(Octanesulfonamido)benzoic Acids as Inhibitors of Glycerol-3-Phosphate Acyltransferase. Medchemcomm. 2014;5(6):826-830.?
molnova catalog
related products
-
Eliglustat
Eliglustat (Tartrate) inhibits?glucosylceramide synthase(GCS),thus reducing the load of glucosylceramide influx into the lysosome.
-
AZD3988
AZD3988 is an orally active and highly potent inhibitor of diacylglycerol acyltransferase-1 (DGAT-1) for the study of diabetes and obesity.
-
FDW028
FDW028 is a selective and potent fucosyltransferase 8 (FUT8) inhibitor with anti-tumor activity that drives B7-H3 lysosomal degradation via defucosylation and CMA pathways. FUT8 can be used to study metastatic colorectal cancer (mCRC).
